Aurora, Colorado 80045


Purpose:

The rationale for fetal therapy in severe congenital diaphragmatic hernia (CDH) is to restore adequate lung growth for neonatal survival.


Study summary:

Prenatal tracheal occlusion (TO) obstructs the normal egress of lung fluid during pulmonary development leading to increased lung tissue stretch, increased cell proliferation, and accelerated lung growth. European colleagues have developed foregut endoscopy and techniques to position and remove endoluminal tracheal balloons in utero. Recently, the Belgium group published summary results of FETO showing an improved survival in 175 patients with isolated left CDH from 24% to 49%. The goal of this pilot study is to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH Observed/expected lung-to-head ratio < 25%(O/E LHR < 25%).


Criteria:

Inclusion Criteria: - Pregnant women age 18 years and older, who are able to consent - Singleton pregnancy Fetal - Normal Karyotype - Fetal Diagnosis of Isolated Left CDH with liver up - Gestation at enrollment prior to 29 wks plus 6 days - SEVERE pulmonary hypoplasia with Uultra Sound O/E LHR < 25% Exclusion Criteria: - Pregnant women <18 years of age. - Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy - Technical limitations precluding fetoscopic surgery - Rubber latex allergy - Preterm labor, cervix shortened (<15 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa - Psychosocial ineligibility, precluding consent - Diaphragmatic hernia: right-sided or bilateral, major associated anomalies, isolated left-sided with the O/E LHR ≥ 25% - Inability to remain at FETO site during time period of tracheal occlusion, delivery and postnatal care


NCT ID:

NCT02530073


Primary Contact:

Principal Investigator
Timothy Crombleholme, MD
University of Colorado, Denver

Jeannie Zuk, PhD
Phone: 720.777.6690
Email: Jeannie.Zuk@childrenscolorado.org


Backup Contact:

N/A


Location Contact:

Aurora, Colorado 80045
United States

Jeannie Zuk, PhD
Phone: 720-777-6690
Email: Jeannie.zuk@childrenscolorado.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.